{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T11:34:01Z","timestamp":1793273641111,"version":"4.5.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.jgar.2026.10.001","type":"journal-article","created":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:05:15Z","timestamp":1791821115000},"page":"212-218","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Comparison of the in vitro activities of ceftazidime-avibactam and ceftolozane-tazobactam against clinical isolates of Pseudomonas aeruginosa: ATLAS global surveillance programme 2020\u20132024"],"prefix":"10.1016","volume":"51","author":[{"given":"Mark A.","family":"Estabrook","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6115-2567","authenticated-orcid":false,"given":"Gregory G.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7535-997X","authenticated-orcid":false,"given":"Katherine K.","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Karlowsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2026.10.001_bib0001","series-title":"AVYCAZ\u00ae prescribing information","year":"2025"},{"key":"10.1016\/j.jgar.2026.10.001_bib0002","series-title":"ZERBAXA\u00ae prescribing information","year":"2022"},{"key":"10.1016\/j.jgar.2026.10.001_bib0003","series-title":"ZAVICEFTA\u00ae prescribing information","year":"2025"},{"key":"10.1016\/j.jgar.2026.10.001_bib0004","doi-asserted-by":"crossref","first-page":"4743","DOI":"10.1128\/AAC.00220-16","article-title":"In vitro susceptibility of global surveillance isolates of Pseudomonas aeruginosa to ceftazidime-avibactam (INFORM 2012 to 2014)","volume":"60","author":"Nichols","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2026.10.001_bib0005","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1093\/jac\/dkx136","article-title":"Activity of ceftolozane\/tazobactam against surveillance and \u2018problem\u2019 Enterobacteriaceae, Pseudomonas aeruginosa, and non-fermenters from the British Isles","volume":"72","author":"Livermore","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2026.10.001_bib0006","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02318-20","article-title":"New perspectives on antimicrobial agents: ceftolozane-tazobactam","volume":"65","author":"Lizza","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2026.10.001_bib0007","doi-asserted-by":"crossref","unstructured":"Tamma PD, Heil EL, Justo JA, et al. Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant Gram-negative infections. 2024; ciae403, https:\/\/doi.org\/10.1093\/cid\/ciae403.","DOI":"10.1093\/cid\/ciae403"},{"key":"10.1016\/j.jgar.2026.10.001_bib0008","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1093\/cid\/ciy378","article-title":"Difficult-to-treat resistance in Gram-negative bacteremia at 173 US hospitals: retrospective cohort analysis of prevalence, predictors, and outcome of resistance to all first-line agents","volume":"67","author":"Kadri","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2026.10.001_bib0009","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: 11th edition: approved standard M07-A12","year":"2024"},{"key":"10.1016\/j.jgar.2026.10.001_bib0010","volume":"M100","year":"2026"},{"key":"10.1016\/j.jgar.2026.10.001_bib0011","unstructured":"EUCAST breakpoint tables for interpretation of MICs and zone diameters. Version 16.0, 2026. Available at http:\/\/www.eucast.org\/clinical_breakpoints\/."},{"key":"10.1016\/j.jgar.2026.10.001_bib0012","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jgar.2019.07.017","article-title":"Activity of ceftolozane-tazobactam and comparators against Pseudomonas aeruginosa from patients in different risk strata \u2013 SMART United States 2016 \u20132017","volume":"20","author":"Lob","year":"2020","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.jgar.2026.10.001_bib0013","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.ijid.2022.10.014","article-title":"Activity of ceftolozane\/tazobactam against clinical isolates of Pseudomonas aeruginosa from patients in the Middle East and Africa \u2013 study for monitoring antimicrobial resistance trends (SMART) 2017-2020","volume":"125","author":"Lob","year":"2022","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jgar.2026.10.001_bib0014","article-title":"Susceptibility profile and \u03b2-lactamase content of global Pseudomonas aeruginosa isolates resistant to ceftolozane\/tazobactam and\/or imipenem\/relebactam\u2212SMART 2016\u221221","volume":"5","author":"Karlowsky","year":"2023","journal-title":"JAC Antimicrob Resist"},{"key":"10.1016\/j.jgar.2026.10.001_bib0015","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jgar.2024.03.020","article-title":"Global trends in carbapenem- and difficult-to-treat-resistance among World Health Organization priority bacterial pathogens: ATLAS surveillance program 2018\u20132022","volume":"37","author":"Wise","year":"2024","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.jgar.2026.10.001_bib0016","doi-asserted-by":"crossref","first-page":"628","DOI":"10.3390\/antibiotics11050628","article-title":"Resistance to ceftazidime\/avibactam, meropenem\/vaborbactam and imipenem\/relebactam in Gram-negative MDR bacilli: molecular mechanisms and susceptibility testing","volume":"11","author":"Gaibani","year":"2022","journal-title":"Antibiot. (Basel)"},{"key":"10.1016\/j.jgar.2026.10.001_bib0017","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1093\/cid\/ciaa381","volume":"72","author":"Karlowsky","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2026.10.001_bib0018","doi-asserted-by":"crossref","first-page":"ofz505","DOI":"10.1093\/ofid\/ofz505","article-title":"Prognostic utility of the new definition of difficult-to-treat resistance among patients with Gram-negative bloodstream infections","volume":"6","author":"Giannelli","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2026.10.001_bib0019","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciaa084","article-title":"Impact of difficult-to-treat resistance in Gram-negative bacteremia on mortality: retrospective analysis of nationwide surveillance data","volume":"71","author":"Huh","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2026.10.001_bib0020","doi-asserted-by":"crossref","DOI":"10.1128\/msphere.00651-22","article-title":"Molecular mechanisms of resistance to ceftazidime\/avibactam in clinical isolates of Enterobacterales and Pseudomonas aeruginosa in Latin American hospitals","volume":"8","author":"Mojica","year":"2023","journal-title":"mSphere"},{"key":"10.1016\/j.jgar.2026.10.001_bib0021","doi-asserted-by":"crossref","first-page":"6407","DOI":"10.1128\/AAC.01282-16","article-title":"Activity of ceftazidime-avibactam against clinical and isogenic laboratory Pseudomonas aeruginosa isolates expressing combinations of the most relevant \u03b2-lactam resistance mechanisms","volume":"60","author":"Torrens","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2026.10.001_bib0022","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01117-20","article-title":"Mechanisms of resistance to ceftolozane\/tazobactam in Pseudomonas aeruginosa: results of the GERPA multicenter study","volume":"65","author":"Fournier","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2026.10.001_bib0023","doi-asserted-by":"crossref","first-page":"6248","DOI":"10.1128\/AAC.00825-15","article-title":"Mutations in \u03b2-lactamase AmpC increase resistance of Pseudomonas aeruginosa isolates to antipseudomonal cephalosporins","volume":"59","author":"Berrazeg","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2026.10.001_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijid.2026.108485","article-title":"Ceftazidime-avibactam versus ceftolozane-tazobactam in the treatment of drug-resistant Pseudomonas aeruginosa: a meta-analysis","volume":"165","author":"Almangour","year":"2026","journal-title":"Int J Infect Dis"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716526001864?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716526001864?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T10:33:37Z","timestamp":1793270017000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716526001864"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":24,"alternative-id":["S2213716526001864"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2026.10.001","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of the in vitro activities of ceftazidime-avibactam and ceftolozane-tazobactam against clinical isolates of Pseudomonas aeruginosa: ATLAS global surveillance programme 2020\u20132024","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2026.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}